Geode Capital Management LLC Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Geode Capital Management LLC grew its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 5.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,667,515 shares of the company’s stock after acquiring an additional 90,543 shares during the period. Geode Capital Management LLC’s holdings in Aquestive Therapeutics were worth $8,306,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of AQST. Financial Advocates Investment Management increased its position in Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after buying an additional 5,000 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter worth $28,000. Charles Schwab Investment Management Inc. increased its holdings in Aquestive Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after acquiring an additional 9,268 shares during the last quarter. SG Americas Securities LLC raised its stake in Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock valued at $128,000 after acquiring an additional 9,496 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics during the second quarter valued at about $27,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AQST shares. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Leerink Partners lifted their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Price Performance

AQST opened at $3.67 on Friday. Aquestive Therapeutics, Inc. has a one year low of $1.98 and a one year high of $6.23. The firm has a market capitalization of $334.62 million, a P/E ratio of -8.16 and a beta of 2.63. The company has a fifty day moving average price of $4.45 and a 200-day moving average price of $4.11.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period last year, the firm posted ($0.03) EPS. On average, analysts expect that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.